Impact of Early Bleeding on Long-Term Mortality Following Left Atrial Appendage Occlusion.

Left atrial appendage occlusion atrial fibrillation bleeding device related thrombosis mortality

Journal

Heart rhythm
ISSN: 1556-3871
Titre abrégé: Heart Rhythm
Pays: United States
ID NLM: 101200317

Informations de publication

Date de publication:
18 Jul 2024
Historique:
received: 10 06 2024
revised: 28 06 2024
accepted: 13 07 2024
medline: 21 7 2024
pubmed: 21 7 2024
entrez: 20 7 2024
Statut: aheadofprint

Résumé

Short-term antithrombotic therapy is recommended after left atrial appendage occlusion(LAAO) to reduce the risk of device-related thrombosis(DRT). However, patients referred for LAAO have excess bleeding risk. Yet, short-term bleeding events post-LAAO are not well characterized. We aimed to evaluate the incidence of early bleeding post-LAAO and its association with long-term mortality risk. We also sought to identify predictors of early bleeding. Patients who underwent LAAO at Mayo Clinic between 2018 and 2023 were included. Early bleeding was defined as bleeding that occurred within three months of discharge. A multivariable Cox proportional hazards model was used to assess the association between early bleeding and death and to estimate the hazard ratio(HR). Multivariable regression analysis was used to identify predictors of early bleeding. Among the 592 patients included, 389(66%) were male, and mean age was 75.6 years. Eighty-three patients(14.0%) experienced early bleeding, with the majority having minimal(63.4%) or minor(17.3%) bleeding. At a median follow-up of 14.4 months(IQR 4.2-27.9), early bleeding after LAAO was associated with an increased risk of all-cause mortality (adjustedHR, 2.07; 95%CI, 1.15-3.75; P=0.02). A history of intracranial bleeding, non-paroxysmal atrial fibrillation, CHA One in seven patients experience a non-procedural bleeding event within 90 days after LAAO. Early bleeding after LAAO is associated with a higher all-cause mortality during mid-term follow-up. Further studies are needed to optimize the management of patients undergoing LAAO.

Sections du résumé

BACKGROUND BACKGROUND
Short-term antithrombotic therapy is recommended after left atrial appendage occlusion(LAAO) to reduce the risk of device-related thrombosis(DRT). However, patients referred for LAAO have excess bleeding risk. Yet, short-term bleeding events post-LAAO are not well characterized.
OBJECTIVE OBJECTIVE
We aimed to evaluate the incidence of early bleeding post-LAAO and its association with long-term mortality risk. We also sought to identify predictors of early bleeding.
METHODS METHODS
Patients who underwent LAAO at Mayo Clinic between 2018 and 2023 were included. Early bleeding was defined as bleeding that occurred within three months of discharge. A multivariable Cox proportional hazards model was used to assess the association between early bleeding and death and to estimate the hazard ratio(HR). Multivariable regression analysis was used to identify predictors of early bleeding.
RESULTS RESULTS
Among the 592 patients included, 389(66%) were male, and mean age was 75.6 years. Eighty-three patients(14.0%) experienced early bleeding, with the majority having minimal(63.4%) or minor(17.3%) bleeding. At a median follow-up of 14.4 months(IQR 4.2-27.9), early bleeding after LAAO was associated with an increased risk of all-cause mortality (adjustedHR, 2.07; 95%CI, 1.15-3.75; P=0.02). A history of intracranial bleeding, non-paroxysmal atrial fibrillation, CHA
CONCLUSIONS CONCLUSIONS
One in seven patients experience a non-procedural bleeding event within 90 days after LAAO. Early bleeding after LAAO is associated with a higher all-cause mortality during mid-term follow-up. Further studies are needed to optimize the management of patients undergoing LAAO.

Identifiants

pubmed: 39032523
pii: S1547-5271(24)02911-4
doi: 10.1016/j.hrthm.2024.07.028
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Gerardo V Lo Russo (GV)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN; Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milan, Milan, Italy.

Abdalla Kara Balla (A)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Hasan Alarouri (H)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Chia-Hao Liu (CH)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN; Division of Cardiology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

Mahmoud Zhour Adi (M)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Ammar M Killu (AM)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

Mohamad Alkhouli (M)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address: Alkhouli.Mohamad@mayo.edu.

Classifications MeSH